Trinity Biotech PLC Trinity Biotech to Announce Q1 2014 Results
16 April 2014 - 1:53PM
RNS Non-Regulatory
Trinity Biotech PLC
16 April 2014
Press Release dated April 16, 2014
Contact: Trinity Biotech plc Lytham Partners LLC
Kevin Tansley Joe Diaz, Joe Dorame & Robert Blum
(353)-1-2769800 602-889-9700
E-mail: kevin.tansley@trinitybiotech.com
Trinity Biotech plc to Announce First Quarter Fiscal Year 2014
Financial Results
Conference Call Scheduled for April 29, 2014
at 11:00 am EASTERN
DUBLIN - April 16, 2014- Trinity Biotech plc (NasdaqGS: TRIB), a
leading developer and manufacturer of diagnostic products for the
point-of-care and clinical laboratory markets, will report
financial results for the first quarter fiscal year 2014 on
Tuesday, April 29, 2014. The Company has scheduled a conference
call for that same day, Tuesday, April 29, 2014 at 11:00am ET
(4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
USA: 1-866-652-5200
International: 1-412-317-6060
Conference ID #: 10044621
A simultaneous webcast of the call can be accessed at:
http://www.videonewswire.com/event.asp?id=98949
A replay of the call can be accessed until May 5, 2014 by
dialing:
USA: 1-877-344-7529
International: 1-412-317-0088
Conference ID #: 10044621
The webcast of the call will be available for 30 days at:
http://www.videonewswire.com/event.asp?id=98949
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems, including both reagents and instrumentation,
for the point-of-care and clinical laboratory segments of the
diagnostic market. The products are used to detect infectious
diseases and to quantify the level of Haemoglobin A1c and other
chemistry parameters in serum, plasma and whole blood. Trinity
Biotech sells direct in the United States, Germany, France and the
U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States
Food and Drug Administration and other agencies, the impact of
competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission.
Contact
Kevin Tansley
Trinity Biotech plc
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Joe Diaz, Joe Dorame and Robert Blum
Lytham Partners, LLC
Investor Relations
602-889-9700
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQKADPBBKDBQD